Market Overview

UPDATE: Piper Jaffray Raises PT to $118 on Edwards Lifesciences on Lower Risks Ahead

Share:
Related EW
Goldman Remains Constructive on MedTech, Sees 'New Opportunities' Amid Selloff
Goldman's New Pair Trade Opportunity
Edwards Completes CardiAQ Buyout, Resolves FORTIS Issue (Zacks)

Piper Jaffray reiterated its Overweight rating on Edwards Lifesciences (NYSE: EW) and increased its price target on shares from $90 to $118 in a research report published Friday.

Piper Jaffray noted, "We are raising our price target on EW reflecting the reduction in risk inherent with the positive national coverage decision (NCD), positive FDA panel meeting on high-risk patients, and the removal of uncertainty related to the outcome of the Supreme Court decision on the Affordable Care Act (ACA)."

Edwards Lifescience closed at $104.44 on Thursday.

Latest Ratings for EW

DateFirmActionFromTo
Aug 2015Credit SuisseAssumesOutperform
Jul 2015Stifel NicolausMaintainsBuy
Jul 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for EW
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Related Articles (EW)

View Comments and Join the Discussion!

Get Benzinga's Newsletters